Symbol
| ATP13A2
| contributors: mct/npt - updated : 23-05-2017
|
HGNC name
| ATPase type 13A2
|
HGNC id
| 30213
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --low
|  
|
plays a role in SNCA misfolding and toxicity | constitutional
|  
|  
|  
|  
|
silencing of ATP13A2 expression in cortical and dopaminergic neurons promotes basal mitochondrial fragmentation and sensitizes to the effects of cadmium exposure | constitutional
|  
|  
|  
| loss of function
|
results in zinc dyshomeostasis and mitochondrial dysfunction | |
Susceptibility
|
to Parkinson disease |
Variant & Polymorphism
other
| rare variant of the ATP13A2 associated with an increased risk of Parkinson disease among ethnic Chinese in Asia Lin 2008) |
|
|
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
neurology | neurodegenerative | Parkinson/dementia Parkinsonism | |
increasing ATP13A2 levels may offer potential therapeutic benefits to patients with Lewy body diseases |
| | | |
| Atp13a2(-/-) mice displayed late-onset sensorimotor deficits |